Tenax Therapeutics, Inc.TENX

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · tenaxthera.com

Tenax Therapeutics, Inc. is a clinical-stage pharmaceutical company developing therapies for cardiovascular and pulmonary disease. Its lead candidate TNX-103, an oral formulation of levosimendan, is being evaluated for pulmonary hypertension due to heart failure with preserved ejection fraction.

Key ratios

ROA

-35.1%2025

2024 -22.5%2023 -68.2%

ROE

-59.8%TTM

2025 -55.6%2024 -35.2%2023 -160.8%

Recent news

Tenax Therapeutics Announces Presentation of Phase 3 LEVEL Results in Late-Breaking Scientific Sessions at ESC Congress 2026 2026-08-29 · GlobeNewswire

Track TENX in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer